CDK4/6 Inhibition Suppresses p73 Phosphorylation and Activates DR5 to Potentiate Chemotherapy and Immune Checkpoint Blockade

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Targeting cyclin-dependent kinases 4 and 6 (CDK4/6) is an effective cancer therapy.
• The precise mechanisms by which CDK4/6 inhibitors exert their antitumor effects, particularly regarding immune responses, are not fully elucidated.

Purpose of the Study:

• To investigate the molecular mechanisms through which CDK4/6 inhibitors enhance antitumor immunity.
• To identify novel pathways regulated by CDK4/6 inhibition that contribute to cancer cell death and therapeutic sensitization.

Main Methods:

• Utilized biochemical assays to determine the interaction and phosphorylation of p73 by CDK4/6.
• Employed cell-based assays and in vivo models to assess the role of p73 and death receptor 5 (DR5) in response to CDK4/6 inhibition.
• Evaluated the impact of CDK4/6 inhibitors on cancer cell sensitivity to chemotherapy and immunotherapy.

Main Results:

• CDK4/6 directly phosphorylates p73 at threonine 86, leading to its cytoplasmic sequestration.
• CDK4/6 inhibition causes p73 dephosphorylation and nuclear translocation, inducing transcription of death receptor 5 (DR5).
• p73-mediated DR5 induction by CDK4/6 inhibitors promotes immunogenic cell death and sensitizes cancer cells to TRAIL, 5-fluorouracil, and anti-PD-1 immunotherapy.
• Deletion of DR5 diminishes the synergistic effects of CDK4/6 inhibitors with other cancer treatments.

Conclusions:

• CDK4/6 inhibitors induce p73-mediated DR5 expression, a novel pathway contributing to cancer cell death.
• This mechanism is critical for enhancing the efficacy of chemotherapy and immune checkpoint blockade.
• DR5 induction by CDK4/6 inhibition represents a potential biomarker and therapeutic target for improving cancer treatment outcomes.